EFFECT OF METASTASIS LOCALIZATION ON SYMPTOMS AND ASSISTANCE COSTS IN ADVANCED NSCLC PATIENTS. FURTHER EVIDENCE FROM THE HABIT STUDY.
Author(s)
Cristina Negrini, DSc, Director1, Alessandra Falcone, MSC, Economic Affairs Officer21Pbe consulting, Milano, Italy; 2 AstraZeneca, Basiglio, MI, Italy
OBJECTIVES: Study aim was to compare symptom severity and home assistance burden in advanced non-small-cell-lung cancer (NSCLC) patients with no metastasis (NM), bony and/or cerebral (BCM) metastases and other metastasis localization (OM). METHODS: A total of 104 advanced NSCLC patients were enrolled in 18 Italian oncology departments and followed up for 3 months. Main caregiver workload was assessed monthly by a task scale; activities of other caregivers were also registered and patients completed the LCS symptoms subscale of the FACT-L questionnaire. Formal caregiving time was valued according to market prices; informal caregiving hours were valued using the wage rate for an equivalent service. RESULTS: Mean age of the total sample was 65.5 years, males' prevalence of was over 80%; principal caregiver was patient's spouse living with the patient and non-working in over 70% of cases. Three-monthly mean total per patient assistance costs amounted to €4431 in BCM, to €2617 and €2716 in OM and NM patients. Cerebral and/or bony metastases caused, upon each monthly check, significantly higher assistance costs referred to the main caregiver (p<0.0001). Higher percentages of patients reported symptoms deterioration in the NM and BCM (45% and 43%) respectively, while only 23% of patients referred symptom worsening in OM. CONCLUSION: Home assistance burden was higher in patient with bony and/or cerebral metastases, other metastasis localizations showed no impact on caregiving costs and symptom severity measured by the LCS subscale.
Conference/Value in Health Info
2006-10, ISPOR Europe 2006, Copenhagen, Denmark
Value in Health, Vol. 9, No.6 (November/December 2006)
Code
PCN34
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology